AÑO: 2009
Dr. Ibrahim Al Khars, MS, MBA, Director Ejecutivo - Almana PharmaCare, Coordinador de los programas académicos y de capacitación en Almana Hospitales Generales en Khobar, Arabia Saudita
Lugar: Dubai D
Hora: 14:30-15:30
No deseable, los desastres médicos han dado forma a la historia y desarrollo de fármacos. Una serie de casos de daños causados a la salud de un gran número de personas debido a los efectos adversos de la "super" fármacos tales como Vioxx (rofecoxib), Agreal (veraliprida), Lipobay (cerivastatina). Esta situación ha hecho que la seguridad del fármaco un problema importante para los gobiernos, las autoridades reguladoras y la industria farmacéutica deben mejorar la gestión de la farmacovigilancia global.
El taller responder preguntas importantes: ¿Por qué los medicamentos dejan de funcionar? ¿Son los medicamentos más seguros hoy en día? Como las drogas se mueven en el entorno de marketing, la pregunta se convierte en uno de seguridad y eficacia "puede funcionar" a una de "qué funciona" en la práctica? "Y ¿Por qué la necesidad de investigar la eficacia?
Objetivos del Taller
Los objetivos principales son
(1) proporcionar definiciones estándar de los términos relacionados con la farmacovigilancia y vigilancia de la seguridad de los medicamentos,
(2) discutir las etapas del desarrollo de medicamentos e identificar la relación con el fracaso de drogas, y
(3) proporcionar orientación técnica sobre los principios de la farmacovigilancia y la inclusión de los medicamentos en los actuales sistemas nacionales de drogas de monitoreo de seguridad.
Este taller permitirá a los participantes a aplicar las herramientas de farmacovigilancia, y dar ejemplos de sufrir eventos médicos, que cambian la historia de las regulaciones droga. Esta sesión interactiva dar una idea de las siguientes áreas:
• ¿Por qué los ensayos clínicos no detectar algunos efectos secundarios?
• Puede vigilancia matasellado decirle si un medicamento es seguro?
• El examen del futuro de la farmacovigilancia en los EE.UU., la UE y los países árabes del Golfo.
• Recomendaciones sobre cómo podemos optimizar los estudios de farmacovigilancia.
.........
Dr. Ibrahim Al Khars, MS, MBA, Executive Director - Almana PharmaCare,
Coordinator of academic and training programs in Almana General Hospitals at Khobar, Saudi Arabia
Venue: Dubai D
Time: 14:30 - 15:30
The workshop will answer important questions: Why do drugs fail? Are drugs safer today? As drugs move into the marketing setting, the question turns from one of safety and efficacy “can it work” to one of “does it work” in actual practice?” and Why the need for Effectiveness Research?
Workshop Objectives
The primary objectives are to
(1) provide standard definitions of terms relating to pharmacovigilance and safety monitoring of drugs,
(2) discuss the stages of drug development and identify the relationship with drug failure, and
(3) provide technical guidance on the principles of good pharmacovigilance and the inclusion of drugs in existing national drug safety monitoring systems.
This workshop will allow participants to apply pharmacovigilance tools, and give examples of serious medical events, which change the history of drug’s regulations. This interactive session will provide insight into the following areas:
• Why clinical trials fail to detect some side-effects?
• Can postmarking surveillance tell whether a drug is safe?
• Examination of the future of pharmacovigilance in the US, EU and Arabian Gulf countries.
• Recommendations on how we can optimize pharmacovigilance studies.
.jpg)
Dr. Ibrahim Al Khars, MS, MBA, Executive Director - Almana PharmaCare,
Coordinator of academic and training programs in Almana General Hospitals at Khobar, Saudi Arabia
Venue: Dubai D
Time: 14:30 - 15:30
Undesirably, medical disasters have shaped the history and development of drugs. A series of cases of damage caused to the health of a large number of people owing to the adverse effects of “super” drugs such as Vioxx (rofecoxib), Agreal (veralipride), Lipobay (Cerivastatin). Such situation has made drug safety a major issue for governments, regulatory authorities and the pharmaceutical industry and improves the management of global pharmacovigilance.
The workshop will answer important questions: Why do drugs fail? Are drugs safer today? As drugs move into the marketing setting, the question turns from one of safety and efficacy “can it work” to one of “does it work” in actual practice?” and Why the need for Effectiveness Research?
Workshop Objectives
The primary objectives are to
(1) provide standard definitions of terms relating to pharmacovigilance and safety monitoring of drugs,
(2) discuss the stages of drug development and identify the relationship with drug failure, and
(3) provide technical guidance on the principles of good pharmacovigilance and the inclusion of drugs in existing national drug safety monitoring systems.
This workshop will allow participants to apply pharmacovigilance tools, and give examples of serious medical events, which change the history of drug’s regulations. This interactive session will provide insight into the following areas:
• Why clinical trials fail to detect some side-effects?
• Can postmarking surveillance tell whether a drug is safe?
• Examination of the future of pharmacovigilance in the US, EU and Arabian Gulf countries.
• Recommendations on how we can optimize pharmacovigilance studies.
.jpg)
No hay comentarios:
Publicar un comentario